company background image
BDTX

Black Diamond Therapeutics NasdaqGS:BDTX Stock Report

Last Price

US$2.27

Market Cap

US$82.4m

7D

12.9%

1Y

-82.3%

Updated

24 Jun, 2022

Data

Company Financials +
BDTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BDTX Stock Overview

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors.

Black Diamond Therapeutics Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Black Diamond Therapeutics
Historical stock prices
Current Share PriceUS$2.27
52 Week HighUS$12.96
52 Week LowUS$1.46
Beta1.45
1 Month Change51.33%
3 Month Change-18.64%
1 Year Change-82.35%
3 Year Changen/a
5 Year Changen/a
Change since IPO-94.25%

Recent News & Updates

Shareholder Returns

BDTXUS BiotechsUS Market
7D12.9%10.3%6.6%
1Y-82.3%-24.4%-18.5%

Return vs Industry: BDTX underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: BDTX underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is BDTX's price volatile compared to industry and market?
BDTX volatility
BDTX Average Weekly Movement10.9%
Biotechs Industry Average Movement13.0%
Market Average Movement8.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: BDTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: BDTX's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201486David M. Epsteinhttps://www.blackdiamondtherapeutics.com

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations.

Black Diamond Therapeutics Fundamentals Summary

How do Black Diamond Therapeutics's earnings and revenue compare to its market cap?
BDTX fundamental statistics
Market CapUS$82.38m
Earnings (TTM)-US$120.80m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BDTX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$120.80m
Earnings-US$120.80m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.33
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did BDTX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BDTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BDTX?

Other financial metrics that can be useful for relative valuation.

BDTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does BDTX's PB Ratio compare to its peers?

BDTX PB Ratio vs Peers
The above table shows the PB ratio for BDTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.7x

Price-To-Book vs Peers: BDTX is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (0.7x).


Price to Earnings Ratio vs Industry

How does BDTX's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Book vs Industry: BDTX is good value based on its Price-To-Book Ratio (0.5x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is BDTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BDTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BDTX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BDTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BDTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BDTX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BDTX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Black Diamond Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-7.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BDTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BDTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BDTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BDTX is forecast to have no revenue next year.

High Growth Revenue: BDTX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BDTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Black Diamond Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-58.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BDTX is currently unprofitable.

Growing Profit Margin: BDTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BDTX is unprofitable, and losses have increased over the past 5 years at a rate of 58% per year.

Accelerating Growth: Unable to compare BDTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BDTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: BDTX has a negative Return on Equity (-70.01%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Black Diamond Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BDTX's short term assets ($188.3M) exceed its short term liabilities ($19.5M).

Long Term Liabilities: BDTX's short term assets ($188.3M) exceed its long term liabilities ($27.5M).


Debt to Equity History and Analysis

Debt Level: BDTX is debt free.

Reducing Debt: BDTX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BDTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BDTX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 59.8% each year.


Discover healthy companies

Dividend

What is Black Diamond Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BDTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BDTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BDTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BDTX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BDTX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

David M. Epstein (62 yo)

5.75yrs

Tenure

US$5,090,225

Compensation

Dr. David M. Epstein, Ph.D. is Co-Founder of Black Diamond Therapeutics, Inc. and serves as its President, Chief Executive Officer and Director at Black Diamond Therapeutics, Inc. since September 2016. He...


CEO Compensation Analysis

Compensation vs Market: David M.'s total compensation ($USD5.09M) is above average for companies of similar size in the US market ($USD758.64K).

Compensation vs Earnings: David M.'s compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: BDTX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: BDTX's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Black Diamond Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Black Diamond Therapeutics, Inc.
  • Ticker: BDTX
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$82.380m
  • Shares outstanding: 36.29m
  • Website: https://www.blackdiamondtherapeutics.com

Number of Employees


Location

  • Black Diamond Therapeutics, Inc.
  • One Main Street
  • 10th Floor
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.